[b]I hate to advocate drugs, alcohol, violence, or insanity to anyone, but they've always worked for me.[/b]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SequestOx needs some serious rethinking
Donut disappoint me now Ama. Your word is gold, "king". 6 days or less.
December 6th then... right?
I agree with you Jour. When results are announced it will be about Isradipine. Elite and Teva likely to be in the background and silent.
Oh.... those $1, $2, $3 prices are coming... and without SequestOx needed.
With SequestOx and the ADF platform once approved much higher than you can imagine. The baskets are beginning to fill.
Gotta love these cheap seat prices though. 8 cents for a share of Isradipine and Adderol IR, ER and Concerta. All coming very soon.
What do all of them make the company worth per share? $4-$5? With all other drugs coming more? I certainly think so.
Where are the 2 cent share prices? The bankruptcy promised?
Nowhere to be seen. Elite is doing just fine.
Not a chance for 2 cent shares or bankruptcy. Pity huh? LMAO~!
Well now..."Prove it" that not a single share has been sold by insiders.
They have to file in order to sell "Doc". Filings tell me no sell.
What do they tell you? Provide proof now.
A great big MAYBE in 9 days or less.
You're welcome~!
newguy, thanks for the PM. Know that I am a fan of NH, having worked in in this sector for the past 18 years. I have a clear understanding of what ELTP as a company is up against, and they do have their work cut out for them as far as the ADF.
As for the other baskets NH has brought up in past discussions, they are beginning to fill. Revenue ramp will be slow at first, but should change over time. And depending on certain outcomes like Isradipine and PD revenues could change for the better in less than a quarter.
I know, because I have seen this type of ramp up in my own place of work.
Hang in..... GLTY
especially true in the case of overvalues stocks like eltp.
The only way one sells Elite for a tax loss is if they overplayed a huge tax gainer. In some cases those who make huge gains in other stocks forget to put a portion of profit aside for tax purposes.
That is about the only circumstance I can think of which would motivate someone to sell his/her shares.
Those are the facts PERIOD~!
Thank you NASDAQ
"Trying to save face"??? In the face of what? LMAO~!
I do not care what the share price is now.
What is important is what is happening, methadone, Percocet, Norco, Isradipine potential, SunGen ANDAs, Glenmark, SunGen, Tagi……
Taking those drugs back from Epic which Epic never executed on.
No matter how small, each revenue is cumulative. It is like boxing. Each revenue from each drug (each punch no matter how powerful) all adds up to a cumulative effect. Till WHAM!!!! Even the big share prices go down.
That is high praise coming from one whose expertise is something I wish I knew more about. Thank you N2K
Jour nice post. Ramp in revenues will be slow at first...… then WHAM~! a quarter to remember followed by more quarters like it.
Now now those that live in glass houses should not be the ones to throw rocks.
To #1 "based on current performance and fundaments.... the revenues are shrinking and the gross margins are abysmal for a generics company" About to turn around with all of that, and I may add that this is a plan that took place years ago by none other than Nasrat Hakim.
Revenues about to upstage with recent approvals of Percocet and Norco. All it takes is a foot in the door. Methadone will start them off slowly for this coming quarter. The following quarter should be interesting.
To #2 "Past performance, did management do what they said they were going to do? in this case, of course it is another failing grade" Past performance is exactly that, past performance. And they did do exactly what they said they were going to do. Notice each basket NH mentioned filling one at a time? And about SequestOx, we just have to see what it will entail thanks in large part to the FDA.
To #3 "Future potential, Nasdaq stocks with no revenues are often mentioned but what is not understood is that these stocks are viewed to have POTENTIAL- again another failing grade for elite "
Say what? Elite no future potential? According to who? Isradipine, already being made, FDA cannot stop them there. SunGen/Elite ANDAs, I doubt the FDA can stop Elite there either. Approvals are coming and a manufacturing/marketing sales base is already in place whether it be
Glenmark or SunGen or another like Tagi. I give NH high marks on all fronts. His plan is finally coming together and all people have to do is buy buy buy, accumulate and hold until a buyout that will not be for a while.
By then Elite will be a force to be reckoned with. Strong pipeline with many generics and a wide assortment of delivery/manufacturing technologies for the buying pharmaceutical.
The facility where I work makes injectable drugs. Want to guess how much money it is pulling down? Not hundreds of millions..... try billions.
Solid dosage in many cases is much easier. So there is close to 1 billion shares outstanding and if Elite even comes close to that in revenue just divide the revenue by the shares outstanding and multiply by 20. Conservative, very conservative for a company likey to have the first line of true ADF prescription opioids.
Gman, give sharpie my best wishes.
Revenues will begin to show themselves slowly over the next few quarters.
Share price should respond as well.
hmmmmmmm let's see that was back when the stock was 8 cents. Where is it now??? ooops 8 cents
A PR from Elite any second now.
Your welcome.
Not a Purdue fan but the Purdue business model and Rudi seem to be doing a great job at keeping Purdue losses due to suits not very damaging to the company so far.
Sackler bunch aka Purdue and this administration pay for play.
Approximately every $50 million in revenue is equal to about $1 in share price with a P/E ratio of 20.
Good times coming around the bend.
Elite should be granted an extension on SequestOx, but knowing this FDA in this time capsule? Who knows....
More than likely they will have to pay to play with this FDA.
but but but I was with a fortune 10 pharmaceutical company.... I know what I am talking about. LMMFAO~!
Since the 14A is found post it. If you can...…..that is....
Pictures of Chris Dick in the break room drinking COF2E2? Shocking indeed.
As long as it isn't El Chapo, I'm good with it.
Yes sireeee~! The gang's all here~! With a hearty Hi Ho Silver~!
You go greenlife.
What's next? Collaboration with Mexican drug cartels?
Yes Elite does have some very large cellars at the facility.
There is no "large" seller. There are, however, buyers that are accumulating. Not much more volume than most longs have at this point.
Spin it anyway you want. It is coming.
About partnering for SequestOx in doing another BE fed intravenous study.... I think NH is willing to wait. Why? Because SequestOx will be just one of a couple of revenue making formulations for Elite. Elite also has to find out about cost of doing this new hoop to jump through from the FDA. Oh, and about the excipient crap from the FDA... what next? Total BS.
When fishing on the rocks late at night with plugs, you cast out and wait until enough line goes out with the tide. You flip the bail and reel in very very slowly letting the current do most of the work. Patience patience patience...… then WHAM~! Got one on. Adrenaline starts to pump.
Same can be done for Elite. Generate enough revenue from your other products to do the full blown BE, intravenous study and practice patience patience patience......
it's all about the money. The new requirement for the assessment of risk by the intravenous rout using SequestOx will require a capital investment ELITE apparently can not afford at the present time. NH stressed that the R&D expenditures will match and add to the bottom line in significantly increased sales and revenue. Look for this increase in revenue, as stated by another poster, to increase quarter by quarter.
NH has not been CEO for 28 years. Jerry saved this company from BK and NH is taking her to the next level. Up to where the big boys play.
BTW, FDA still riding shotgun for Purdue. OxyContin still in the mix, only the FDA has set NEW (stalling) requirements. Human abuse liability studies have to be done? Really? Since when did Purdue do any? They weren't required otherwise the FDA would have nixed OxyContin long ago.
Again pay for play. Protect those like Purdue for political reasons.
So sad.
Yes. it is all coming together. Getting Isradipine ready for what may come. Methadone in two doses, now more opportunity.
Loxapine and Dantrolene coming back to Elite.
And Dr Fatmi leaves due to a conflict of interest. Parent company does not like their employees to be part of another company's BoD. So no ties.
Still Elite keeps their relationship with Dr Fatmi intact. So much the better.
It is starting to come together.
Just listened to the CC. Everything is coming together.SOme of the generics are nice little revenue makers such as Dantrolene, $7 million total, but only one other competitor.
And as I thought Elite will more than likely bundle Percocet, Norco and possibly the Codeine APAP with a contract manufacturer.
SequestOx still in the mix as well as OxyContin. With OxyContin the FDA
now requires HAL studies to be done. My question to the FDA...… did Purdue do as much?
Overall, very optimistic CC starting this Q coming.
Not very speculative in my opinion. I think you are on point toofun.
Epic(PuraCap) and Elite are basically done. The new player is SunGen's parent company, and SunGen as well.
When SequestOx failed the reformulation in the first go around you could hear it in NH's voice. And when pursuing a new formulation to address the Tmax issue you could sense optimism but also you could sense he was unsure of how it would go.
There are reasons why NH said things would be happening between the last CC and this CC. They have happened and even more is happening that we don't know of...…. that is my take on the situation.
imanjen BINGO~! You hit the nail on the head.
So Elite will be bought out for $1/share? Does not make sense.
My take on this was that in looking for a possible replacement for Pfieffer
Fatmi was an obvious choice. I don't think the HumanWell relationship went all that well. Lots pf stuff not completed when PuraCap took Epic over.
Epic did not seem to give Elite much of a heads up on buyout. Generics Epic was supposed to get to their production for Elite never happened. In my company they call that a breach of contract.
Buyout not coming soon IMO. Still way too early. Elite/SunGen has to get their formulations on the market to prove viability in the market place.
Just too many irons in the fire right now. Pipeline is rich but yet untapped.
Bye bye Dr Fatmi.